Domestic covid-19 medicine has big news again!
On May 18, the national infectious diseases Medical Center, Zhang Wenhong’s team of Huashan infection and fan Xiaohong’s team of Shanghai public health completed an open and prospective cohort study to evaluate the effect of vv116 on the negative time of nucleic acid in patients with non severe Omicron virus infection. The results were published in the journal emerging microbes & infections on the same day. The results showed that the nucleic acid negative conversion time of domestic anti covid-19 virus drug vv116 in patients with non severe Omicron infection could be significantly shortened by 2-3 days. According to the Research Report of Tianfeng Securities Co.Ltd(601162) , this drug is related to Shanghai Junshi Biosciences Co.Ltd(688180) .
from the market level, the flash collapse market reappears today. At the opening of trading on May 18, the share price of “Jiayuan series” created by Zhejiang tycoon Shen Tianqing plunged one after another. The share price of Jiayuan international fell by more than 40%, and the decline of Jiayuan service was more than 70%. Then the stock was suspended urgently. So, what happened
Yao Ming system also fell sharply, and both Wuxi Apptec Co.Ltd(603259) and Yao Ming biology once fell by nearly 6%. According to a survey report by Citigroup, 27% of respondents are likely to change partners after providing UVL definition. This may be the main reason for the sharp decline of YaoMing system. So how big is the impact?
Zhang Wenhong heavy
According to a number of media reports such as Yicai, on May 18, the research jointly conducted by the national infectious diseases Medical Center, Shanghai Key Laboratory of infectious diseases and biosafety emergency response, Professor Zhang Wenhong’s team of Huashan infection, Professor Fan Xiaohong’s team of Shanghai public health clinical center and Lingang laboratory was published, The results showed that the nucleic acid negative conversion time of domestic anti covid-19 virus drug vv116 in patients with non severe Omicron infection could be significantly shortened by 2-3 days.
this is an open and prospective cohort study. The relevant results were published in the journal emerging microbes & infections on May 18. This is also the first peer-reviewed article published by Chinese researchers on the research results of domestic anti covid-19 drugs on Omicron infection
It is reported that 136 people were enrolled in this test. The data show that those infected with Omicron virus use vv116 within 5 days after the first positive nucleic acid test, and the nucleic acid negative time is 8.56 days (vs. 11.13 days in the control group). In addition, vv116 given to symptomatic patients within 2-10 days after the first nucleic acid positive can also shorten the time of nucleic acid negative conversion. No serious adverse reactions were observed, and all subjects did not develop to severe. Compared with the real-world study of paxlovid conducted by Shenzhen Third Hospital, the nucleic acid conversion time of the experimental group was 9.92 days (vs 12.17 days in the control group), and the results of vv116 nucleic acid conversion data were close, and the results were in line with expectations.
Tianfeng Securities Co.Ltd(601162) medical research team said that vv116 two mild and moderate disease phase III trials are progressing smoothly, and it is expected that data will be read out in the near future. At present, Shanghai Junshi Biosciences Co.Ltd(688180) has carried out two clinical trials for mild to moderate covid-19 patients:
1) the international multicenter phase III clinical trial has enrolled a certain number of patients in Shanghai, and the clinical trial in Hong Kong has also started recently. The trial plans to enroll patients in many places around the world to provide support for new drug market applications worldwide.
2) phase III clinical trial conducted in China with Pfizer specific drug paxlovid head-to-head non inferior. At present, the enrollment of patients has been completed, and the data is expected to be read out in the near future. Head to head clinical trial data with paxlovid will initially show the efficacy of vv116, which is conducive to market approval and later sales.
In addition, Shanghai Junshi Biosciences Co.Ltd(688180) also deployed 3clpro inhibitor vv993, which is under development. The synergistic combination of the two drugs is expected to solve the possible problem of drug resistance. Vv993 is a Shanghai Junshi Biosciences Co.Ltd(688180) layout 3clpro inhibitor with the same mechanism as Pfizer paxlovid. At present, according to the preclinical and antiviral research results of vv993, vv993 single drug shows good effectiveness and safety, and has important development value. Vv116 and vv993 play a role in different key and conservative targets in the virus life cycle, and have the development prospect of combined drugs.
Shanghai Junshi Biosciences Co.Ltd(688180) recently, the share price trend has been relatively strong, but it has been corrected in recent trading days.
Zhejiang rich encounter Black Swan
From the market point of view, although the recent good news continues, the phenomenon of individual stock flash collapse occurs from time to time. It’s Jiayuan’s turn today.
At the opening of trading on May 18, the share price of “Jiayuan series” created by Zhejiang tycoon Shen Tianqing plunged across the board. Jiayuan international shares plunged more than 40%.
Jiayuan services fell by 70%.
on January 17, 2019, Jiayuan International’s share price plunged 83% due to the storm of “debt default”, and its market value instantly shrank by more than HK $26 billion. Since then, Jiayuan international has been basically in a long-term downturn
Analysts believe that the flash collapse may be related to the downgrade of major banks. On May 10, Moody’s announced that it would downgrade Jiayuan International’s rating from “B2” to “B3” and its senior unsecured rating from “B3” to “caa1”. At the same time, it also adjusted its outlook for Jiayuan international from the rating on the watch list to negative. Moody’s pointed out in the rating report that the downgrade was related to the slightly weak performance of Jiayuan International Holdings and its weakening liquidity.
Statistics show that the helm of Jiayuan international is Shen Tianqing. In 1991, Shen resigned and went to the sea. In 1995, he founded Zhejiang Jiayuan real estate, which can be regarded as starting from real estate. In his words, “when I was an official, I couldn’t feel it. Later, I decided to go to the sea. I’m a swimmer.”
Data show that the company’s sales in the first four months of 2022 almost halved, only 892 million. According to the company’s financial report in 2021, the company’s short-term borrowings are as high as 3.628 billion yuan, and the short-term notes and convertible bonds due in one year are 2.842 billion yuan, which may mean that the company will have more than 6 billion debts due this year.
Yaoming system fell again
It is also worth mentioning that Yao Ming system.
Over the past year, YaoMing’s individual stocks have collapsed and plummeted many times. Today, they have plummeted again. Both Wuxi Apptec Co.Ltd(603259) and Yaoming biology once plummeted nearly 6%, and then stabilized. So what happened?
Analysts believe that there may be two reasons:
First, fund-raising. On May 16, Wuxi Apptec Co.Ltd(603259) H shares announced that the company plans to issue new H shares, and the number of issued H shares shall not exceed 20% of the number of issued H shares (i.e. no more than about 784342 million shares). If calculated according to the latest closing price of HK $96 per share, the amount of this offering will exceed HK $7.52 billion. The capital market has many views on this fund-raising.
Second, a research report of Citibank. According to Citigroup’s survey, when selecting cro / cdmo partners, in addition to quality and cost, the existing strategic cro / cdmo partnership is one of the most important attributes, and geopolitical risk is not one of them. However, cooperation with more than one cro / cdmo will be the main countermeasure to diversify geopolitical risks. According to the survey report, most respondents are not familiar with the unverified list (UVL), and about 27% of respondents said that they are likely to change partners after the definition of UVL is completed, mainly because it involves internal compliance requirements and reputation risk.
From the perspective of the whole market, the trading volume of A-share market has not been effectively enlarged. Under the background of the sharp rebound of RMB and peripheral markets, A-Shares still appear to be not strong enough the main reason may still be related to uncertain economic expectations and the stabilization and rebound of US bond yields
